Foamix Pharmaceuticals Ltd.
www.foamix.com
Latest From Foamix Pharmaceuticals Ltd.
Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
Menlo’s Setback Not Expected To Affect Results In Lead Pruritus Indication
With Foamix merger closing soon, Menlo’s serlopitant failed a Phase II trial in chronic pruritus of unknown origin, but the firm said a Phase III program in prurigo nodularis shouldn’t be affected. Its share in the new company is contingent on the PN data.
Deal Watch: Allergan Keeps After Hair Loss With Exicure Deal
Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.
Keeping Track: Vertex’ Trikafta Speeds To US Approval; New Indications For AZ’s Farxiga, J&J’s Stelara, GSK’s Zejula
The latest drug development news and highlights from our US FDA Performance Trackers.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
- Topical Delivery
- Transdermal
-
Drug Delivery
- Therapeutic Areas
- Dermatology
- Infectious & Viral Diseases
- Inflammation
- Alias(es)
- Foamix Ltd.
- Ownership
- Public
- Headquarters
-
Worldwide
-
Middle East
-
Israel
-
Israel
-
Middle East
- Parent & Subsidiaries
- Foamix Pharmaceuticals Ltd.
- Senior Management
-
David Domzalski, CEO
Ilan Hadar, CFO
Matt Wiley, Chief Commercial Officer
Russell Elliott, PhD, SVP, Pharmaceutical Dev.
Iain Stuart, PhD, CSO
Deepa Desai, VP, Reg. Affairs - Contact Info
-
Foamix Pharmaceuticals Ltd.
Phone: (972) 8 9316233
Weizmann Science Park
2 Holzman St.
Rehovot, 7670402
Israel